Bridging Global Disparities in Drug Allergy Through AI ‐Assisted Training for Non‐Specialists: Findings From the Multinational ADAPT ‐2 Course
Clinical & Experimental Allergy · 2026-02 · 56 (2) · 137-146
DOI: 10.1111/cea.70213 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical & Experimental Allergy, online erschienen am 20.01.2026. Verfasst von Hugo W F Mak und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Artificial Intelligence. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Clinical Specialties Fund, Sichuan Science and Technology Program.
Abstract (Originalsprache)
Background
Mislabelled drug allergy (DA) remains a global public health challenge. A prior randomised trial (ADAPT) demonstrated that an intensive educational course improved DA knowledge and confidence among non‐specialists. However, ADAPT was restricted to English‐speaking participants and its generalisability remains unknown. To address this, a multinational implementation study expanding ADAPT (ADAPT‐2) was performed.
Methods
Non‐allergist physicians from Colombo (Sri Lanka), Guangzhou and Shenzhen (Mainland China), Hong Kong (Special Administrative Region of China) and Perth (Australia) completed a standardised DA educational course. In Mainland China, training was delivered via AI‐assisted video localisation (converted into Mandarin while preserving the speaker's voice with lip‐synced adaptation). DA knowledge, confidence and practice were assessed before and after completion. Subgroup analyses compared pre–post changes between Advanced Economies (AE: Australia, Hong Kong) and Emerging Economies (EE: Mainland China, Sri Lanka).
Results
Of 181 participants, overall baseline knowledge (53.5% ± 17.2%) and confidence (47.5% ± 22.7%) scores were suboptimal. EE participants had a lower knowledge level than AE (49.1% ± 15.5% vs. 70.1% ± 12.7%; p < 0.001). Following ADAPT‐2, both knowledge (72.5% ± 16.0%, p < 0.001) and confidence (71.3% ± 17.5%, p < 0.001) scores significantly improved across all groups. ADAPT‐2 delivered by AI‐assisted video localisation was non‐inferior to the English course in effectiveness ( p > 0.05) and achieved high participant satisfaction (98.9% as ‘somewhat clear’ or better in clarity).
Conclusions
Deficits in DA knowledge persist widely among non‐specialists, with marked disparities between AE and EE. ADAPT‐2 bridged these gaps by universal improvements in both DA knowledge and confidence. AI‐assisted training represents a scalable, equitable strategy for global implementation of standardised and evidence‐based DA education. Trial Registration ADAPT: NCT06399601
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China.
- Department of Allergy and Immunology, West China Hospital, Sichuan University, Chengdu, China.
- Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
- Department of Allergy, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
- Division of Rheumatology & Clinical Immunology, Department of Medicine, University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China.
- Medical School, University of Western Australia, Nedlands, Western Australia, Australia.
ORCID-Profile: Hugo W F Mak, Juan Meng, Jin-Xian Huang, Jason A Trubiano, Philip H Li
Förderung
- National Key Clinical Specialties Fund
- Sichuan Science and Technology Program
Zitieren
APA
Mak, H. W. F., Meng, J., Chung, F. K. L., Lee, J. T. Y., Aberathna, I. S., Amarasekara, U., Ranasinghe, T. N. D., Jayamali, J., Yang, Q., Zhou, M., Chen, L., Huang, J. X., Shi, W., Kulkarni, R., Peter, J. G., Trubiano, J. A., Jeewandara, K. C., Lucas, M., & Li, P. H. (2026). Bridging Global Disparities in Drug Allergy Through AI ‐Assisted Training for Non‐Specialists: Findings From the Multinational ADAPT ‐2 Course. Clinical & Experimental Allergy, 56(2), 137-146. https://doi.org/10.1111/cea.70213
Vancouver
Mak HWF, Meng J, Chung FKL, Lee JTY, Aberathna IS, Amarasekara U, et al. Bridging Global Disparities in Drug Allergy Through AI ‐Assisted Training for Non‐Specialists: Findings From the Multinational ADAPT ‐2 Course. Clinical & Experimental Allergy. 2026;56(2):137-146. doi:10.1111/cea.70213
BibTeX
@article{Mak2026,
author = {Mak, Hugo W F and Meng, Juan and Chung, Freya K L and Lee, Jasmine T Y and Aberathna, Inoka Sepali and Amarasekara, Uvini and Ranasinghe, Thushali N D and Jayamali, Jeewantha and Yang, Qintai and Zhou, Min and Chen, Liang and Huang, Jin-Xian and Shi, Weihong and Kulkarni, Rishabh and Peter, Jonny Grant and Trubiano, Jason A and Jeewandara, Kamal Chandima and Lucas, Michaela and Li, Philip H},
title = {Bridging Global Disparities in Drug Allergy Through AI ‐Assisted Training for Non‐Specialists: Findings From the Multinational ADAPT ‐2 Course},
journal = {Clinical & Experimental Allergy},
year = {2026},
volume = {56},
number = {2},
pages = {137--146},
doi = {10.1111/cea.70213}
}
EUVIMED